Vunakizumab ELISA Kit|乌纳基单抗ELISA检测试剂盒(靶标：乌纳基单抗酶联免疫检测试剂盒)
- 货号：RB9TDS856078
- 价格：面议
- 点击：215
产品介绍
产品参数
| 应用 | ELISA |
|---|---|
| 检测方法 | Colorimetric |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 样本类型 | Plasma, Serum |
| 检测类型 | Quantitative |
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 运输条件 | 2-8 ℃ |
| 登录号 | Q16552 |
| 背景信息 | Vunakizumab is a recombinant humanized IgGκ monoclonal antibody binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). It was discovered and developed by Jiangsu Hengrui Medicine (China) with the developmental name SHR-1314, for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. Atridia Pty. Ltd., which is now a part of Jiangsu Hengrui Medicine, start a phase-I clinical trial in psoriasis (in volunteers) in Australia in August 2016. Atridia completed the phase-I trial in July 2017. A phase-I/II study, which is started from December 2017, is ongoing to assess the safety, tolerability, and pharmacokinetics of SHR-1314 with expanded dose finding in subjects with moderate-to-severe plaque psoriasis. |
| 别名 | SHR-1314, 1792181-33-9 |
| 备注 | For Research Use Only. |
相关产品: